116 related articles for article (PubMed ID: 16181707)
1. Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL37) in normal mice.
Irwin N; Green BD; Gault VA; Cassidy RS; O'Harte FP; Harriott P; Flatt PR
Peptides; 2006 Apr; 27(4):893-900. PubMed ID: 16181707
[TBL] [Abstract][Full Text] [Related]
2. Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).
Irwin N; Gault VA; Green BD; Greer B; Harriott P; Bailey CJ; Flatt PR; O'Harte FP
Biol Chem; 2005 Jul; 386(7):679-87. PubMed ID: 16207089
[TBL] [Abstract][Full Text] [Related]
3. Stable agonist of glucose-dependent insulinotropic polypeptide (GIP) restores pancreatic beta cell glucose responsiveness but not glucose intolerance in aging mice.
Irwin N; Green BD; Gault VA; Harriot P; O'Harte FP; Flatt PR
Exp Gerontol; 2006 Feb; 41(2):151-6. PubMed ID: 16378704
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
[TBL] [Abstract][Full Text] [Related]
5. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice.
Irwin N; Gault VA; Green BD; Greer B; McCluskey JT; Harriott P; O'Harte FP; Flatt PR
Biol Chem; 2004 Sep; 385(9):845-52. PubMed ID: 15493880
[TBL] [Abstract][Full Text] [Related]
6. Effects of subchronic treatment with the long-acting glucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in streptozotocin-induced diabetes.
Gault VA; McClean PL; Irwin N; Power GJ; McCluskey JT; Flatt PR
Pancreas; 2007 Jul; 35(1):73-9. PubMed ID: 17575548
[TBL] [Abstract][Full Text] [Related]
7. A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.
Irwin N; Green BD; Mooney MH; Greer B; Harriott P; Bailey CJ; Gault VA; O'Harte FP; Flatt PR
J Pharmacol Exp Ther; 2005 Sep; 314(3):1187-94. PubMed ID: 15923344
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.
Irwin N; McClean PL; Cassidy RS; O'harte FP; Green BD; Gault VA; Harriott P; Flatt PR
Diabetes Metab Res Rev; 2007 Oct; 23(7):572-9. PubMed ID: 17315241
[TBL] [Abstract][Full Text] [Related]
9. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.
Kerr BD; Irwin N; O'Harte FP; Bailey CJ; Flatt PR; Gault VA
Biochem Pharmacol; 2009 Oct; 78(8):1008-16. PubMed ID: 19523458
[TBL] [Abstract][Full Text] [Related]
10. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
11. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
12. Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice.
Porter DW; Irwin N; Flatt PR; Hölscher C; Gault VA
Eur J Pharmacol; 2011 Jan; 650(2-3):688-93. PubMed ID: 21050845
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice.
Irwin N; Hunter K; Flatt PR
Peptides; 2007 Nov; 28(11):2192-8. PubMed ID: 17884253
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
Irwin N; McClean PL; Flatt PR
J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
[TBL] [Abstract][Full Text] [Related]
15. Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets.
Cassidy RS; Irwin N; Flatt PR
Biol Chem; 2008 Feb; 389(2):189-93. PubMed ID: 18163884
[TBL] [Abstract][Full Text] [Related]
16. Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intolerance.
Kerr BD; Irwin N; Flatt PR; Gault VA
Peptides; 2009 Feb; 30(2):219-25. PubMed ID: 19026698
[TBL] [Abstract][Full Text] [Related]
17. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
McClean PL; Irwin N; Cassidy RS; Holst JJ; Gault VA; Flatt PR
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1746-55. PubMed ID: 17848629
[TBL] [Abstract][Full Text] [Related]
18. Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice.
Irwin N; Hunter K; Frizzell N; Flatt PR
Regul Pept; 2009 Feb; 153(1-3):70-6. PubMed ID: 19073224
[TBL] [Abstract][Full Text] [Related]
19. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.
Irwin N; McClean PL; O'Harte FP; Gault VA; Harriott P; Flatt PR
Diabetologia; 2007 Jul; 50(7):1532-40. PubMed ID: 17486314
[TBL] [Abstract][Full Text] [Related]
20. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
